Concepts (250)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Oropharyngeal Neoplasms | 35 | 2025 | 265 | 8.210 |
Why?
|
| Papillomavirus Infections | 37 | 2025 | 385 | 8.010 |
Why?
|
| Carcinoma, Squamous Cell | 30 | 2024 | 754 | 2.990 |
Why?
|
| Human papillomavirus 16 | 18 | 2025 | 97 | 2.980 |
Why?
|
| Papillomaviridae | 18 | 2023 | 179 | 2.300 |
Why?
|
| Head and Neck Neoplasms | 18 | 2025 | 637 | 2.090 |
Why?
|
| Alphapapillomavirus | 5 | 2022 | 47 | 1.830 |
Why?
|
| Mouth Neoplasms | 9 | 2026 | 99 | 1.690 |
Why?
|
| DNA, Viral | 6 | 2025 | 453 | 1.620 |
Why?
|
| Antibodies, Viral | 6 | 2025 | 1167 | 1.390 |
Why?
|
| Early Detection of Cancer | 6 | 2025 | 420 | 1.380 |
Why?
|
| Oncogene Proteins, Viral | 4 | 2025 | 61 | 1.230 |
Why?
|
| Papillomavirus Vaccines | 5 | 2022 | 111 | 1.140 |
Why?
|
| Anus Neoplasms | 3 | 2022 | 42 | 1.030 |
Why?
|
| Uterine Cervical Neoplasms | 5 | 2022 | 262 | 1.000 |
Why?
|
| Salivary Gland Neoplasms | 2 | 2026 | 64 | 0.950 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2026 | 16 | 0.950 |
Why?
|
| Smoking | 11 | 2023 | 923 | 0.890 |
Why?
|
| Circulating Tumor DNA | 1 | 2025 | 42 | 0.860 |
Why?
|
| Sexual Behavior | 4 | 2018 | 238 | 0.800 |
Why?
|
| Mouth Diseases | 1 | 2023 | 16 | 0.790 |
Why?
|
| Middle Aged | 48 | 2026 | 28511 | 0.720 |
Why?
|
| Penile Neoplasms | 1 | 2021 | 18 | 0.690 |
Why?
|
| Alcohol Drinking | 6 | 2016 | 344 | 0.680 |
Why?
|
| Biomarkers, Tumor | 4 | 2025 | 1613 | 0.600 |
Why?
|
| Health Care Costs | 3 | 2020 | 403 | 0.600 |
Why?
|
| Male | 51 | 2026 | 64763 | 0.580 |
Why?
|
| Condylomata Acuminata | 1 | 2018 | 12 | 0.580 |
Why?
|
| Case-Control Studies | 17 | 2023 | 3393 | 0.550 |
Why?
|
| Microbiota | 1 | 2023 | 438 | 0.540 |
Why?
|
| Prognosis | 14 | 2026 | 4910 | 0.530 |
Why?
|
| Mouth | 1 | 2018 | 64 | 0.530 |
Why?
|
| Cancer Survivors | 1 | 2020 | 272 | 0.500 |
Why?
|
| Humans | 68 | 2026 | 130854 | 0.490 |
Why?
|
| Neoplasm Staging | 9 | 2026 | 1311 | 0.450 |
Why?
|
| Aged | 32 | 2026 | 20970 | 0.450 |
Why?
|
| Female | 51 | 2026 | 70550 | 0.440 |
Why?
|
| Vaccination | 2 | 2018 | 1042 | 0.410 |
Why?
|
| Laryngeal Neoplasms | 3 | 2020 | 86 | 0.340 |
Why?
|
| Prospective Studies | 7 | 2024 | 6448 | 0.340 |
Why?
|
| Prevalence | 8 | 2023 | 2694 | 0.320 |
Why?
|
| Sex Distribution | 5 | 2019 | 315 | 0.310 |
Why?
|
| Texas | 9 | 2026 | 3635 | 0.310 |
Why?
|
| Age Distribution | 5 | 2018 | 424 | 0.300 |
Why?
|
| Mass Screening | 3 | 2025 | 808 | 0.290 |
Why?
|
| Risk Factors | 18 | 2023 | 10978 | 0.290 |
Why?
|
| Adult | 25 | 2026 | 31238 | 0.290 |
Why?
|
| Insurance, Health | 2 | 2019 | 139 | 0.270 |
Why?
|
| SEER Program | 2 | 2026 | 211 | 0.250 |
Why?
|
| Medicaid | 2 | 2019 | 251 | 0.250 |
Why?
|
| Reference Values | 5 | 2017 | 679 | 0.250 |
Why?
|
| Incidence | 9 | 2020 | 3336 | 0.240 |
Why?
|
| In Situ Hybridization | 2 | 2017 | 441 | 0.230 |
Why?
|
| Logistic Models | 4 | 2017 | 1805 | 0.230 |
Why?
|
| Polymerase Chain Reaction | 5 | 2019 | 1457 | 0.220 |
Why?
|
| Age Factors | 3 | 2020 | 2841 | 0.220 |
Why?
|
| Cost-Benefit Analysis | 3 | 2020 | 548 | 0.210 |
Why?
|
| Cohort Studies | 7 | 2017 | 5095 | 0.210 |
Why?
|
| Longitudinal Studies | 2 | 2021 | 1493 | 0.210 |
Why?
|
| Social Determinants of Health | 1 | 2026 | 165 | 0.210 |
Why?
|
| Smokers | 2 | 2020 | 48 | 0.200 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2018 | 146 | 0.200 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2022 | 3428 | 0.200 |
Why?
|
| Follow-Up Studies | 7 | 2018 | 5199 | 0.200 |
Why?
|
| Retrospective Studies | 10 | 2022 | 17673 | 0.200 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2017 | 784 | 0.200 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2020 | 1082 | 0.190 |
Why?
|
| Anus Diseases | 1 | 2022 | 15 | 0.190 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2022 | 2849 | 0.190 |
Why?
|
| Vulvar Neoplasms | 1 | 2022 | 20 | 0.190 |
Why?
|
| Cotinine | 3 | 2008 | 26 | 0.190 |
Why?
|
| Proportional Hazards Models | 5 | 2024 | 1405 | 0.180 |
Why?
|
| Carcinoma in Situ | 1 | 2022 | 69 | 0.180 |
Why?
|
| Polymorphism, Genetic | 5 | 2016 | 778 | 0.180 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2023 | 379 | 0.180 |
Why?
|
| Mouthwashes | 1 | 2021 | 10 | 0.170 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 1279 | 0.170 |
Why?
|
| Neoplasms, Second Primary | 2 | 2013 | 140 | 0.170 |
Why?
|
| Pharyngeal Neoplasms | 3 | 2008 | 19 | 0.170 |
Why?
|
| Healthcare Disparities | 1 | 2026 | 507 | 0.170 |
Why?
|
| Tongue Neoplasms | 1 | 2020 | 30 | 0.160 |
Why?
|
| Cross-Sectional Studies | 4 | 2023 | 3807 | 0.160 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2020 | 14 | 0.160 |
Why?
|
| Sex Factors | 3 | 2018 | 1342 | 0.160 |
Why?
|
| Radiotherapy Dosage | 1 | 2020 | 221 | 0.160 |
Why?
|
| MicroRNAs | 2 | 2018 | 896 | 0.160 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2020 | 103 | 0.160 |
Why?
|
| Smoking Cessation | 2 | 2020 | 191 | 0.160 |
Why?
|
| Tobacco Products | 1 | 2020 | 60 | 0.150 |
Why?
|
| Direct Service Costs | 1 | 2019 | 11 | 0.150 |
Why?
|
| Capsid Proteins | 2 | 2018 | 148 | 0.150 |
Why?
|
| DNA-Binding Proteins | 4 | 2015 | 1977 | 0.150 |
Why?
|
| Squamous Intraepithelial Lesions of the Cervix | 1 | 2019 | 3 | 0.150 |
Why?
|
| Oropharynx | 2 | 2013 | 31 | 0.150 |
Why?
|
| Bayes Theorem | 1 | 2020 | 308 | 0.150 |
Why?
|
| Aged, 80 and over | 4 | 2026 | 6797 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2019 | 117 | 0.150 |
Why?
|
| United States | 7 | 2020 | 11865 | 0.150 |
Why?
|
| Repressor Proteins | 1 | 2003 | 776 | 0.140 |
Why?
|
| Academic Medical Centers | 2 | 2017 | 318 | 0.140 |
Why?
|
| Genital Neoplasms, Female | 1 | 2019 | 41 | 0.140 |
Why?
|
| Anal Canal | 1 | 2019 | 85 | 0.140 |
Why?
|
| Cause of Death | 1 | 2020 | 504 | 0.140 |
Why?
|
| Risk Assessment | 5 | 2017 | 3694 | 0.140 |
Why?
|
| Odds Ratio | 4 | 2016 | 1215 | 0.140 |
Why?
|
| Survival Analysis | 3 | 2024 | 1501 | 0.130 |
Why?
|
| Body Mass Index | 1 | 2024 | 1681 | 0.130 |
Why?
|
| DNA Nucleotidyltransferases | 1 | 1997 | 20 | 0.130 |
Why?
|
| Alcohols | 1 | 1997 | 14 | 0.130 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 584 | 0.130 |
Why?
|
| Lymphocytes | 3 | 2016 | 348 | 0.130 |
Why?
|
| Biopsy, Needle | 1 | 2017 | 207 | 0.130 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1997 | 123 | 0.130 |
Why?
|
| Linear Models | 1 | 2018 | 689 | 0.120 |
Why?
|
| Genes, p16 | 1 | 2016 | 11 | 0.120 |
Why?
|
| Fungal Proteins | 1 | 1997 | 136 | 0.120 |
Why?
|
| Respiratory Tract Infections | 1 | 2019 | 295 | 0.120 |
Why?
|
| Recombinational DNA Repair | 1 | 2016 | 17 | 0.120 |
Why?
|
| Young Adult | 4 | 2020 | 10040 | 0.120 |
Why?
|
| Genotype | 8 | 2022 | 2606 | 0.120 |
Why?
|
| Models, Statistical | 1 | 2018 | 482 | 0.120 |
Why?
|
| DNA Repair | 3 | 2005 | 577 | 0.120 |
Why?
|
| RNA Helicases | 1 | 2015 | 75 | 0.110 |
Why?
|
| Apoptosis | 2 | 2016 | 1844 | 0.110 |
Why?
|
| Cancer Care Facilities | 2 | 2016 | 32 | 0.110 |
Why?
|
| Adolescent | 5 | 2021 | 20818 | 0.110 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 277 | 0.110 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1997 | 402 | 0.100 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 1612 | 0.100 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2014 | 95 | 0.100 |
Why?
|
| Extremities | 1 | 2013 | 74 | 0.100 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 2113 | 0.100 |
Why?
|
| Telomere Homeostasis | 1 | 2013 | 48 | 0.100 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2013 | 52 | 0.100 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2013 | 33 | 0.100 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2013 | 125 | 0.100 |
Why?
|
| Disease-Free Survival | 3 | 2024 | 903 | 0.090 |
Why?
|
| Survival Rate | 3 | 2024 | 2140 | 0.090 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 896 | 0.090 |
Why?
|
| Confidence Intervals | 2 | 2010 | 269 | 0.090 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 294 | 0.090 |
Why?
|
| Demography | 1 | 2012 | 238 | 0.090 |
Why?
|
| Registries | 2 | 2026 | 1617 | 0.090 |
Why?
|
| Sarcoma | 1 | 2013 | 219 | 0.080 |
Why?
|
| Biomarkers | 1 | 2020 | 3400 | 0.080 |
Why?
|
| Pilot Projects | 4 | 2023 | 1457 | 0.080 |
Why?
|
| Time Factors | 1 | 2020 | 6217 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2010 | 79 | 0.080 |
Why?
|
| Medical History Taking | 1 | 2010 | 109 | 0.080 |
Why?
|
| Binding Sites | 3 | 2018 | 1149 | 0.080 |
Why?
|
| Tumor Virus Infections | 1 | 2010 | 131 | 0.080 |
Why?
|
| Immunoglobulin G | 3 | 2015 | 790 | 0.070 |
Why?
|
| Disease Progression | 1 | 2015 | 2212 | 0.070 |
Why?
|
| Codon | 1 | 2008 | 92 | 0.070 |
Why?
|
| Dronabinol | 1 | 2008 | 29 | 0.070 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2008 | 48 | 0.070 |
Why?
|
| Carcinogens | 1 | 2008 | 129 | 0.070 |
Why?
|
| Seroepidemiologic Studies | 1 | 2008 | 165 | 0.070 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2008 | 93 | 0.060 |
Why?
|
| Occupational Exposure | 1 | 2008 | 138 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2020 | 12913 | 0.060 |
Why?
|
| Surgical Flaps | 1 | 2008 | 180 | 0.060 |
Why?
|
| Secondary Prevention | 2 | 2020 | 219 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 2112 | 0.060 |
Why?
|
| Gastrostomy | 1 | 2005 | 86 | 0.050 |
Why?
|
| Gastroesophageal Reflux | 1 | 2008 | 333 | 0.050 |
Why?
|
| G2 Phase | 1 | 2004 | 39 | 0.050 |
Why?
|
| Gamma Rays | 1 | 2004 | 39 | 0.050 |
Why?
|
| Genome-Wide Association Study | 2 | 2022 | 1842 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2008 | 729 | 0.050 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2003 | 21 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2022 | 2566 | 0.050 |
Why?
|
| Lymphatic Metastasis | 2 | 2016 | 428 | 0.050 |
Why?
|
| State Medicine | 1 | 2022 | 23 | 0.050 |
Why?
|
| 17-Hydroxysteroid Dehydrogenases | 1 | 2022 | 8 | 0.050 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2022 | 14 | 0.050 |
Why?
|
| Endonucleases | 1 | 2002 | 51 | 0.050 |
Why?
|
| Canada | 1 | 2022 | 323 | 0.040 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2022 | 107 | 0.040 |
Why?
|
| Thyroid Neoplasms | 1 | 2004 | 250 | 0.040 |
Why?
|
| Risk | 1 | 2003 | 729 | 0.040 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2001 | 18 | 0.040 |
Why?
|
| Nutrition Surveys | 1 | 2023 | 327 | 0.040 |
Why?
|
| Vagina | 1 | 2022 | 200 | 0.040 |
Why?
|
| DNA Helicases | 1 | 2002 | 237 | 0.040 |
Why?
|
| Mass Vaccination | 1 | 2020 | 14 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 1380 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2023 | 813 | 0.040 |
Why?
|
| Genitalia, Female | 1 | 2019 | 44 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2020 | 308 | 0.040 |
Why?
|
| Patient Preference | 1 | 2020 | 150 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2020 | 293 | 0.030 |
Why?
|
| DNA | 1 | 2023 | 1420 | 0.030 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2019 | 230 | 0.030 |
Why?
|
| Genetic Complementation Test | 1 | 1997 | 89 | 0.030 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2016 | 17 | 0.030 |
Why?
|
| Proteins | 1 | 2002 | 1016 | 0.030 |
Why?
|
| Hydrolysis | 1 | 1997 | 140 | 0.030 |
Why?
|
| Glycerol | 1 | 1997 | 78 | 0.030 |
Why?
|
| Camptothecin | 1 | 2016 | 77 | 0.030 |
Why?
|
| Substrate Specificity | 1 | 1997 | 285 | 0.030 |
Why?
|
| Viral Core Proteins | 1 | 2016 | 17 | 0.030 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 1 | 2015 | 14 | 0.030 |
Why?
|
| Mutagenesis | 1 | 1997 | 328 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2003 | 1935 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2015 | 155 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2002 | 1555 | 0.030 |
Why?
|
| Helicobacter pylori | 1 | 2005 | 1367 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2020 | 1228 | 0.030 |
Why?
|
| Helicobacter Infections | 1 | 2005 | 1307 | 0.030 |
Why?
|
| Kinetics | 1 | 1997 | 1089 | 0.030 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2016 | 141 | 0.030 |
Why?
|
| Computational Biology | 1 | 2020 | 868 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 771 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 2924 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2016 | 361 | 0.030 |
Why?
|
| ROC Curve | 1 | 2015 | 607 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 528 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 1997 | 1324 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2013 | 157 | 0.020 |
Why?
|
| Genome | 1 | 2016 | 464 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 1215 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 164 | 0.020 |
Why?
|
| Base Sequence | 1 | 1997 | 2764 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2002 | 2454 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2013 | 392 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 1234 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 1997 | 3497 | 0.020 |
Why?
|
| Cocarcinogenesis | 1 | 2010 | 15 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2016 | 2906 | 0.020 |
Why?
|
| Quality of Life | 1 | 2020 | 2082 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 1125 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 3727 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 2303 | 0.020 |
Why?
|
| Immunoassay | 1 | 2008 | 125 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2005 | 132 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2004 | 120 | 0.010 |
Why?
|
| Patient Selection | 1 | 2008 | 723 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 1797 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2019 | 15016 | 0.010 |
Why?
|
| Exons | 1 | 2005 | 765 | 0.010 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2002 | 19 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2002 | 65 | 0.010 |
Why?
|
| Antibodies, Bacterial | 1 | 2005 | 412 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2002 | 286 | 0.010 |
Why?
|
| Alleles | 1 | 2005 | 1689 | 0.010 |
Why?
|
| Child | 1 | 2019 | 26215 | 0.010 |
Why?
|
| Alcoholism | 1 | 2001 | 244 | 0.010 |
Why?
|
| Comorbidity | 1 | 2001 | 1587 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2005 | 4017 | 0.010 |
Why?
|